Co-Diagnostics Joint Venture, CoSara, Invited to Participate in 2nd Advanced TB Diagnostics Course in Chennai, India

Co-Diagnostics (Nasdaq: CODX) said its joint venture CoSara Diagnostics was invited to the 2nd Advanced TB Diagnostics Course in Chennai, India, held Dec 15–19, 2025 at ICMR–NIRT.

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) said its joint venture CoSara Diagnostics was invited to the 2nd Advanced TB Diagnostics Course in Chennai, India, held Dec 15–19, 2025 at ICMR–NIRT.

The multi-day workshop, hosted with McGill International TB Centre and global partners, brings national TB programs, diagnostics developers, industry and experts from WHO, Gates Foundation, FIND and academic institutions to review the diagnostics value chain, new technologies, cost-effectiveness modeling, policy development and strategies to close the TB case-finding gap across the South‑East Asian Region.

Argus Dec 18 session

+5.31% close to close 1.2x rel. volume Open Argus

Details

News Market Reaction – CODX

On Dec 18, the day this news came out, CODX closed 5.31% above the previous close.

Data tracked by StockTitan Argus for the Dec 18 session.

Key Figures

Workshop dates: December 15-19, 2025 Program length: Five-day program Course edition: 2nd Advanced TB Diagnostics Course

Workshop dates

December 15-19, 2025

2nd Advanced TB Diagnostics Course in Chennai, India

Program length

Five-day program

Advanced TB diagnostics and implementation workshop

Course edition

2nd Advanced TB Diagnostics Course

Regional capacity-building workshop for SEAR countries

Historical Context

5 past events · Latest: Dec 17

5 events

1. Dec 17

   Influenza assay update

   24h Move

   +6.5%

   In silico analysis confirmed Logix Smart ABC coverage of H3N2 mutation.

2. Dec 09

   Platform AI presentation

   24h Move

   +4.5%

   Conference presentation on portable Co-Dx PCR platform and AI integration.

3. Dec 08

   CoSara virology meeting

   24h Move

   -7.4%

   CoSara VIROCON presence and Phase I/II MTB and HPV preclinical data.

4. Nov 20

   TB conference address

   24h Move

   -5.8%

   Address on MTB test adoption and potential India/South Africa rollout.

5. Nov 18

   Respiratory trial start

   24h Move

   +13.4%

   Initiation of clinical evaluations for upper respiratory multiplex POC test.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tuberculosis, diagnostics value chain, cost-effectiveness modeling, evidence-based policy

4 terms

tuberculosis medical

"address emerging needs in tuberculosis detection, research, and implementation"

A contagious bacterial infection that most often attacks the lungs and can range from a mild, slow-developing illness to a severe, long-lasting disease. It matters to investors because its prevalence, treatment options, diagnostic tests and public health policies drive demand for medicines, vaccines and medical services; like a smoldering fire, outbreaks and progress in therapies can quickly change market size, regulatory priorities and company valuations.

diagnostics value chain technical

"The workshop includes sessions covering the full diagnostics value chain, highlights"

The diagnostics value chain is the series of steps that take a medical test from idea to use: research and development, regulatory approval, manufacturing, distribution, laboratory or point‑of‑care testing, and reporting of results. Think of it like an assembly line that not only builds a product but also delivers and explains it to the customer. Investors care because strengths or bottlenecks at any step affect costs, speed to market, revenue predictability and regulatory risk, all of which shape returns.

cost-effectiveness modeling technical

"highlights new technologies in the innovation pipeline, examines cost-effectiveness modeling"

A quantitative way to compare the costs and health benefits of medical treatments or technologies to see which gives the most value for money. Think of it like comparing two cars by both price and fuel efficiency: investors use these models to predict whether a product will be adopted, reimbursed by insurers or governments, and able to earn returns based on projected uptake and pricing.

evidence-based policy technical

"cost-effectiveness modeling and evidence-based policy development, and explores"

A decision-making approach that uses reliable data, research and measurable outcomes to design and evaluate policies so actions are based on what has been shown to work rather than opinion or tradition. For investors, evidence-based policy matters because it tends to make regulatory and spending decisions more predictable and transparent, reducing surprise risks and helping assess how government choices may affect sectors, company profits and long-term market trends.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Dec. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its joint venture, CoSara Diagnostics Pvt. Ltd. ("CoSara"), has been invited to participate in the 2nd Advanced TB Diagnostics Course, a capacity-building workshop for countries in the South-East Asian Region (SEAR). The event will take place December 15-19, 2025 at the ICMR–National Institute for Research in Tuberculosis (NIRT) located in Chennai, India. 

Hosted by ICMR-NIRT in partnership with the McGill International TB Centre and other global health organizations, the multi-day workshop brings together leading experts, national TB programs, diagnostics developers and industry partners to address emerging needs in tuberculosis detection, research, and implementation. The workshop includes sessions covering the full diagnostics value chain, highlights new technologies in the innovation pipeline, examines cost-effectiveness modeling and evidence-based policy development, and explores practical strategies to close the TB case-finding gap across SEAR nations.

The five-day program will also feature presentations and panel discussions led by national and international faculty, including experts from WHO, The Gates Foundation, FIND, Boston University, and India's central TB institutions. Industry innovators will additionally present technology pitches highlighting emerging diagnostic solutions.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-joint-venture-cosara-invited-to-participate-in-2nd-advanced-tb-diagnostics-course-in-chennai-india-302645600.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CoSara Diagnostics' role at the 2nd Advanced TB Diagnostics Course in Chennai Dec 15–19, 2025?

CoSara Diagnostics was invited to participate among industry partners to present and engage in sessions across the diagnostics value chain.

How does Co-Diagnostics (CODX) benefit from CoSara's participation in the Chennai TB diagnostics workshop?

Participation increases CoSara's visibility with national TB programs and global health organizations, supporting networking and technology exposure.

Which organizations and experts will present at the Dec 15–19, 2025 TB diagnostics course in Chennai?

Presenters include WHO, Gates Foundation, FIND, McGill International TB Centre, Boston University and India's central TB institutions.

What topics will the 2nd Advanced TB Diagnostics Course in Chennai cover for CODX/CoSara?

The workshop covers the diagnostics value chain, new technologies, cost-effectiveness modeling, evidence-based policy, and case-finding strategies.

Will CoSara present a technology pitch or product at the Chennai workshop?

The workshop program includes industry technology pitches, and CoSara was invited to participate among industry innovators.